FAIT, Tomas, Tivadar BALTAZAR, Leona BUBENÍČKOVÁ, Jan KESTRANEK, Martin STEPAN, Miroslav MULLER a Pavel TURCAN. Treatment of Vulvovaginal Laxity by Electroporation: The Jett Plasma Medical for Her II Study. Journal of Clinical Medicine. Basel: MDPI, 2023, roč. 12, č. 19, s. 1-12. ISSN 2077-0383. Dostupné z: https://dx.doi.org/10.3390/jcm12196234.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Treatment of Vulvovaginal Laxity by Electroporation: The Jett Plasma Medical for Her II Study
Autoři FAIT, Tomas (203 Česká republika), Tivadar BALTAZAR (203 Česká republika), Leona BUBENÍČKOVÁ (203 Česká republika, domácí), Jan KESTRANEK (203 Česká republika), Martin STEPAN (203 Česká republika), Miroslav MULLER (203 Česká republika) a Pavel TURCAN (203 Česká republika, garant).
Vydání Journal of Clinical Medicine, Basel, MDPI, 2023, 2077-0383.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30214 Obstetrics and gynaecology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.900 v roce 2022
Kód RIV RIV/00216224:14110/23:00133376
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/jcm12196234
UT WoS 001085248800001
Klíčová slova anglicky vaginal laxity; vulvovaginal laxity; nonsurgical vaginal tightening; incontinence; sexual function; urogenital distress; electroporation therapy
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 1. 2. 2024 10:59.
Anotace
Introduction: Vaginal laxity is a widespread and undertreated medical condition associated especially with vaginal parity. Aim: To evaluate the efficacy and safety of electroporation therapy treatment of vulvovaginal laxity by the Jett Plasma for Her II device. Methods: The Jett Plasma for Her II Study is a multicentric, prospective, randomized, single-blinded, and controlled study. Women presenting with vaginal laxity were randomized to receive electroporation therapy delivered to the vaginal tissue (active-82 patients) vs. therapy with zero intensity (placebo-9 patients). Results: A total of 91 subjects whose average age was 48.69 +/- 10.89 were included. Due to the results of a one-way analysis of variance, it may be concluded that in the case of the vaginal laxity questionnaire (VLQ), there is a statistically significant difference between actively treated patients and the placebo group (F-1,F-574 = 46.91; p < 0.001). In the case of the female sexual function index (FSFI), a one-way ANOVA test also showed a statistically significant difference between the actively treated patients and the placebo group (F-1,F-278 = 7.97; p = 0.005). In the case of the incontinence impact questionnaire-7 (IIQ-7), a one-way ANOVA test showed a statistically significant difference between the actively treated patients and the placebo group (F-1,F-384 = 15.51; p < 0.001). It confirms that improvement of vaginal laxity is conjoined with benefits in symptoms of urinary incontinence. Biopsy performed after the end of the treatment shows an increase in the vaginal mucosa thickness by an average of 100.04% in the active group. The treatment was well tolerated with no adverse events. No topical anesthetics were required. Conclusions: Treatments of vulvovaginal laxity by electroporation therapy achieved significant and sustainable 12-month effectiveness. Responses to the questionnaires also suggest subjective improvement in self-reported sexual function, incontinence, sexual satisfaction, and urogenital distress.
VytisknoutZobrazeno: 23. 7. 2024 21:27